Xiangxue Pharmaceutical Financial Flexibility Index
Xiangxue Pharmaceutical financial flexibility index. Xiangxue Pharmaceutical (300147) has a Financial Flexibility Index of 0.01x as of September 2025. Free cash flow of CN¥81.38 Million (operating CF CN¥75.64 Million minus capex CN¥5.74 Million) represents 0% of total liabilities (CN¥6.27 Billion). See 300147 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Xiangxue Pharmaceutical (2007–2025)
Financial flexibility index of Xiangxue Pharmaceutical from 2007 to 2025. Historical Financial Flexibility Index trend for Xiangxue Pharmaceutical across 19 annual periods. Check 300147 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Xiangxue Pharmaceutical Financial Flexibility Index by Year (2007–2025)
Xiangxue Pharmaceutical financial flexibility index by year from 2007 to 2025. Year-by-year free cash flow to debt coverage for Xiangxue Pharmaceutical. For the full cash flow conversion analysis, see Xiangxue Pharmaceutical (300147) cash flow conversion.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.02x | CN¥161.15 Million | CN¥139.63 Million | CN¥6.70 Billion | ▲ +172.8% |
| 2024 | 0.01x | CN¥53.42 Million | CN¥18.17 Million | CN¥6.06 Billion | ▼ -83.5% |
| 2023 | 0.05x | CN¥319.48 Million | CN¥263.44 Million | CN¥5.97 Billion | ▼ -41.2% |
| 2022 | 0.09x | CN¥594.65 Million | CN¥227.38 Million | CN¥6.53 Billion | ▼ -15.4% |
| 2021 | 0.11x | CN¥820.30 Million | CN¥257.56 Million | CN¥7.62 Billion | ▼ -38.4% |
| 2020 | 0.17x | CN¥964.60 Million | CN¥257.18 Million | CN¥5.53 Billion | ▲ +2.1% |
| 2019 | 0.17x | CN¥744.11 Million | CN¥83.02 Million | CN¥4.35 Billion | ▲ +34.5% |
| 2018 | 0.13x | CN¥586.70 Million | CN¥91.24 Million | CN¥4.61 Billion | ▼ -20.4% |
| 2017 | 0.16x | CN¥887.40 Million | CN¥109.53 Million | CN¥5.56 Billion | ▼ -68.2% |
| 2016 | 0.50x | CN¥2.16 Billion | CN¥198.48 Million | CN¥4.30 Billion | ▲ +27.3% |
| 2015 | 0.39x | CN¥436.84 Million | CN¥159.89 Million | CN¥1.11 Billion | ▲ +65.6% |
| 2014 | 0.24x | CN¥409.43 Million | CN¥165.58 Million | CN¥1.72 Billion | ▼ -35.0% |
| 2013 | 0.37x | CN¥646.92 Million | CN¥328.37 Million | CN¥1.76 Billion | ▼ -3.6% |
| 2012 | 0.38x | CN¥537.03 Million | CN¥118.91 Million | CN¥1.41 Billion | ▼ -26.6% |
| 2011 | 0.52x | CN¥260.24 Million | CN¥29.55 Million | CN¥502.16 Million | ▲ +141.1% |
| 2010 | 0.21x | CN¥102.33 Million | CN¥45.47 Million | CN¥476.01 Million | ▼ -21.7% |
| 2009 | 0.27x | CN¥99.04 Million | CN¥46.19 Million | CN¥360.69 Million | ▼ -49.6% |
| 2008 | 0.54x | CN¥193.44 Million | CN¥55.72 Million | CN¥354.94 Million | ▼ -30.2% |
| 2007 | 0.78x | CN¥282.75 Million | CN¥138.02 Million | CN¥361.98 Million | — |